What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Diroximel fumarate is expected to be as clinically effective as dimethyl fumarate, which is already recommended for active relapsing-remitting multiple sclerosis. The evidence from the clinical trial indicates that both treatments have similar efficacy, supported by pharmacokinetic analyses demonstrating bioequivalence. The committee concluded that diroximel fumarate and dimethyl fumarate are expected to be equally effective, which supports a clear clinical advantage.
Does the economic case hold at the expected price? — Cost effectiveness
The cost comparison analysis indicates that the total costs associated with diroximel fumarate are similar to or lower than those associated with dimethyl fumarate. Given that both treatments are expected to provide similar health benefits, diroximel fumarate is considered clearly cost-effective under common thresholds.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that diroximel fumarate is associated with fewer gastrointestinal side effects compared to dimethyl fumarate, which can significantly impact patients’ daily functioning and overall well-being. Patient expert submissions indicated that gastrointestinal side effects are less likely to interfere with daily activities, suggesting a moderate improvement in quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Diroximel fumarate has a better safety profile than dimethyl fumarate, with fewer gastrointestinal side effects reported in clinical trials. Although some side effects like flushing were noted, they were described as mostly mild to moderate and less likely to lead to treatment discontinuation. This indicates a very good tolerability overall.
Was the drug compared against what payers expect? — Comparator Selection
The comparator, dimethyl fumarate, is a relevant and appropriate choice as it is a widely prescribed treatment for the same condition and has been previously recommended by NICE. The committee concluded that the comparison with dimethyl fumarate is appropriate, fulfilling the criteria for ideal comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The proposed population for diroximel fumarate aligns well with NICE’s recommendations for active relapsing-remitting multiple sclerosis. The committee noted that the population included in the recommendation is consistent with the company’s proposal, indicating broad generalizability with minor subgroup gaps.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Diroximel fumarate can be self-administered at home, similar to other oral disease-modifying treatments, which means no significant changes in service provision or management are needed. This indicates a minor adjustment is required for integration into existing healthcare pathways.
Are the wider system costs understood? — Resource Use and Cost Implications
The analysis indicates that the total costs associated with diroximel fumarate are similar to or lower than those associated with dimethyl fumarate, suggesting a notable but justifiable cost burden with proportional benefits. The commercial arrangement also supports manageable budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a phase-3 randomized controlled trial, which provides a strong foundation for the conclusions drawn. However, there are some limitations regarding the generalizability of the findings, which prevents a higher rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there is some uncertainty regarding the long-term outcomes and the impact of the commercial arrangement, the overall context is favorable, with a clear unmet need for effective treatments in this patient population. This mitigates some of the uncertainty.
